Zabofloxacin
Names | |
---|---|
Preferred IUPAC name
1-Cyclopropyl-6-fluoro-7-[(8E)-8-(methoxyimino)-2,6-diazaspiro[3.4]octan-6-yl]-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid | |
Other names
DW-224a
| |
Identifiers | |
3D model (
JSmol ) |
|
ChemSpider | |
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C19H20FN5O4 | |
Molar mass | 401.392 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Zabofloxacin (DW-224a) is an investigational
fluoroquinolone antibiotic for multidrug-resistant infections due to Gram-positive bacteria.[1][2][3][4] It also has activity against Neisseria gonorrhoeae including strains that are resistant to other quinolone antibiotics.[5]
Zabofloxacin was discovered by Dong Wha Pharmaceuticals and licensed to Pacific Beach BioSciences for development.[6]
A double-blind, three-arm clinical study of the drug began in March 2010.[7]
References
- S2CID 11071210.
- S2CID 96104286.
- S2CID 13284436.
- PMID 27869677.
- PMID 18620833.
- ^ "Pacific Beach BioSciences and Dong Wha Pharmaceuticals Sign Exclusive License Agreement to Develop and Commercialize Zabofloxacin (PB-101, DW-224a)". GlobeNewswire. August 10, 2007.
- ^ IASO Pharma Inc. (2012-05-04). "A Phase 2, Multi-Dose, Double-Blind, Double-Dummy, Active-Control, Randomized Study to Evaluate the Safety, Efficacy and Pharmacokinetic Profile of Two Dosing Regimens of Zabofloxacin for the Treatment of Community-Acquired Pneumonia of Moderate Severity".